Publications by authors named "S Youngberg"
Background: The Pediatric Acute Care Cardiology Collaborative (PAC3) is a learning network focused on improving acute care cardiology patient outcomes. Data submission timeliness is a vulnerability for PAC3 and most clinical registries, directly affecting collaborative benchmarking, quality improvement (QI) and research projects.
Objective: PAC3 conducted a collaborative-wide QI project addressing data timeliness and efficiency.
Infection with hepatitis C virus is the leading indication for liver transplantation and most common cause of infectious disease-related mortality in the United States. BZF961 is a novel inhibitor of the hepatitis C virus NS3-4A protease. This sequential, three part exploratory first-in-human study investigated the safety and pharmacokinetics of single and multiple ascending oral doses of BZF961 in healthy subjects.
View Article and Find Full Text PDFBioavailability and pharmacokinetic profile of a newly-developed twice-a-day sustained-release paracetamol formulation.
Int J Clin Pharmacol Ther
February 2015
Objective: A new twice daily sustained-release (SR) paracetamol formulation was developed to improve convenience and enhance patient compliance for treatment of pain from chronic diseases. This research aimed to evaluate bioavailability and compare pharmacokinetic (PK) properties of the new SR paracetamol formulation (2x1,000 mg) with those of immediate-release (IR) paracetamol (2x500 mg) and existing extended-release (ER) paracetamol (2x665 mg).
Methods: Two randomized, single-dose, 4-way crossover studies were conducted.
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Clin Infect Dis
March 2013
Article Synopsis
- Boceprevir, a new treatment for hepatitis C, showed significant pharmacokinetic interactions with ritonavir-boosted protease inhibitors (PI/r) in a study involving 39 healthy adults.
- The study found that coadministering boceprevir decreased the blood levels of all tested PI/r drugs, with notable reductions of 22%-36% in ritonavir exposure and 32%-45% in boceprevir levels when combined with other protease inhibitors.
- Overall, while the treatments were well tolerated, the reduced drug levels could potentially lower the effectiveness of both boceprevir and the PI/r medications when taken together.
Objective: Nonsteroidal anti-inflammatory drugs (NSAIDs) can induce renal complications in patients taking loop diuretics. This study investigated the pharmacokinetic/pharmacodynamic effects and safety profile of orally administered diclofenac sodium, ibuprofen and diclofenac epolamine topical patch (DETP) on furosemide in healthy adult subjects.
Methods: This open-label, randomized, 5-way crossover study was conducted in 40 subjects (aged 19 - 45 y).